Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies
Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.
Sartorius Stedim Biotech has signed a contract to acquire the majority stake in the US start-up, AllPure Technologies LLC. The privately owned company based in New Oxford, PA, has been in operation for four years, and earned revenue of approximately $3 million in 2013 with 25 employees. AllPure specializes in single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.
Source: Sartorius Stedim Biotech
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
